EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Antithrombotic Treatment for Left Ventricular Assist Devices: One Does Not Fit All

Emmanuelle Scala iD, Alexandra Othenin-Girard iD

Hämostaseologie · 01.02.2025 · 45 (01) · 080-088

DOI: 10.1055/a-2487-6365 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hämostaseologie, erschienen am 01.02.2025. Verfasst von Emmanuelle Scala und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, Cardiothoracic and Vascular Anaesthesia, Lausanne University Hospital (CHUV), Lausanne, Switzerland. Hauptthemen laut MEDLINE: Heart-Assist Devices, Fibrinolytic Agents, Heart Failure, Thrombosis. Die Arbeit nennt 80 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the prevalence of heart failure is increasing globally, left ventricular assist devices (LVADs) have become essential therapeutic options in managing advanced heart failure. This review explores the development of LVAD technology, with a focus on the shift from pulsatile to continuous-flow devices, particularly the HeartMate 3, the most advanced generation of LVADs. The evolution in design has significantly enhanced patient survival and quality of life. However, hemocompatibility-related adverse events (HRAEs)—such as pump thrombosis, ischemic and hemorrhagic strokes, and gastrointestinal bleeding—remain major clinical challenges. Striking the delicate balance between preventing thromboembolic events and minimizing hemorrhagic risks remains critical in LVAD patient management. Current therapeutic strategies typically involve long-term anticoagulation with vitamin K antagonists and antiplatelet therapy, though optimal management must be individualized based on patient-specific factors and device characteristics. Emerging alternatives, including low-dose anticoagulation, direct oral anticoagulants such as apixaban, and aspirin-free regimens, offer promising potential to reduce adverse outcomes. This review also highlights the role of innovative mechanical designs in minimizing shear stress and alternative treatments in preventing complications like gastrointestinal bleeding. Despite these advancements, personalized treatment strategies are critical, as no single therapeutic regimen fits all LVAD recipients. Ongoing research into both device technology and pharmacological therapies is essential to further reduce HRAEs and improve long-term outcomes for LVAD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesFibrinolytic AgentsHeart FailureThrombosisHumansAnticoagulantsPlatelet Aggregation Inhibitors

Substanzen

Fibrinolytic AgentsAnticoagulantsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Anaesthesiology, Cardiothoracic and Vascular Anaesthesia, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Faculty of Biology and Medicine, University of Lausanne (UNIL), Lausanne, Switzerland.

ORCID-Profile: Emmanuelle Scala, Alexandra Othenin-Girard

Zitieren

APA

Scala, E., & Othenin-Girard, A. (2025). Antithrombotic Treatment for Left Ventricular Assist Devices: One Does Not Fit All. Hämostaseologie, 45(01), 080-088. https://doi.org/10.1055/a-2487-6365

Vancouver

Scala E, Othenin-Girard A. Antithrombotic Treatment for Left Ventricular Assist Devices: One Does Not Fit All. Hämostaseologie. 2025;45(01):080-088. doi:10.1055/a-2487-6365

BibTeX
@article{Scala2025,
  author = {Scala, Emmanuelle and Othenin-Girard, Alexandra},
  title = {Antithrombotic Treatment for Left Ventricular Assist Devices: One Does Not Fit All},
  journal = {Hämostaseologie},
  year = {2025},
  volume = {45},
  number = {01},
  pages = {080--088},
  doi = {10.1055/a-2487-6365}
}
Kostenlos starten →